Ponoi Management, LLC
Follow13F filer, CIK 1720702, San Francisco, CA
Ponoi Management, LLC reported $174,792,000 across 5 holdings for the quarter ended 2020-12-31, in a 13F-HR filed 2021-02-16.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-21-002048
Changes against Q3 2020 are not shown: it was a notice, with the holdings in another manager's report (0 positions on file), so every position would read as new.
- Period
- 2020-12-31
- Reported value
- $175M
- Holdings
- 5
- Top 10 weight
- 100%
- New
- Sold out
Holdings, Q4 2020
Share positions as resolved from 13F-HR 0000950123-21-002048, largest first. % of portfolio is the value over $174,792,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICAL | 1,880,623 | $54.2M | 30.99% | ||||
| NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INC | 1,298,908 | $39.4M | 22.52% | ||||
| RAPT THERAPEUTICS INCRAPT THERAPEUTICS INC | 1,599,417 | $31.6M | 18.07% | ||||
| RVMDREVOLUTION MEDICINES INC | 685,011 | $27.1M | 15.52% | Timeline | |||
| NRIXNURIX THERAPEUTICS INC | 686,274 | $22.6M | 12.91% | Timeline |
How Q4 2020 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000950123-21-002048 | base | 2021-02-16 | acceptance time not in the bulk data set |